U.S. Pharma Stock News

In February 2026, American States Water reported fourth-quarter 2025 diluted earnings per share of US$0.74 and outlined plans to invest US$185 million to US$225 million in capital expenditures during 2026, with adjusted results showing improvement in its core water business versus the prior year. This combination of stronger underlying water segment earnings and a sizeable 2026 investment program highlights management’s focus on reinforcing long-term infrastructure and operational...

Recent trading in Sila Realty Trust (SILA) has been influenced by Truist Securities maintaining a positive view after the latest quarterly update, where earnings per share missed expectations but revenue came in slightly ahead of forecasts. See our latest analysis for Sila Realty Trust. At a share price of US$25.03, Sila Realty Trust has seen a 1-day share price return of 1.38% and a 90-day share price return of 11.05%. Its 1-year total shareholder return of 5.07% and 3-year total shareholder...

Mosaic (NYSE:MOS) has entered a joint agreement with Rainbow Rare Earths to advance the Uberaba rare earths project in Brazil. The partners plan to process phosphogypsum, a fertilizer byproduct, to produce rare earths such as neodymium and praseodymium. The initiative expands Mosaic’s business focus beyond fertilizers into materials used in clean energy and high tech applications. Mosaic, trading at $29.15, is better known for its fertilizers, so this rare earths move gives investors a...

Celldex Therapeutics recently presented new and additional positive Phase 2 and open-label extension data on its antibody barzolvolimab in chronic inducible urticaria subtypes at the 2026 AAAAI Annual Meeting, showing rapid improvements in urticaria control on both initial and repeat treatment. A key insight from these results is that many patients who initially achieved complete response in cold urticaria or symptomatic dermographism regained similar disease control after retreatment,...

Event overview and recent price context Tronox Holdings (TROX) has drawn attention after recent share price volatility, with the stock down about 10% over the past month but up roughly 43% in the past 3 months. For investors, that mix of short term weakness and stronger recent momentum raises questions about how the current US$6.76 share price lines up with Tronox Holdings' value score of 4 and its reported financial profile. See our latest analysis for Tronox Holdings. Looking beyond the...

If you are wondering whether International Business Machines (IBM) still offers value at around US$248.87 per share, you are not alone. This article will help you frame that question clearly. The stock has slipped about 0.5% over the last week and 16.0% over the last month, while still showing a 2.2% return over 1 year and a very large gain over 3 and 5 years. Recent headlines have focused on IBM's positioning as a major software and services player, with investors reassessing how its mix of...

Valvoline (NYSE:VVV) has launched the Happy to Help Fund in partnership with Blue Grass Community Foundation to back mental and physical well-being projects for children and youth in Lexington. The company has named Jordan M. Denny as Chief Accounting Officer and Controller, marking a key update to its executive leadership team. For you as an investor, this pairs a fresh community initiative with a leadership change at a company best known for vehicle lubricants, services, and related...

Super Group (SGHC) recently reported its Q4 results, highlighting record customer numbers, rising deposits, the completion of a major African tech migration, and the launch of its ZAR Supercoin in South Africa. The company also returned US$156 million to shareholders and raised its quarterly dividend target, underlining a stronger focus on capital returns alongside product innovation. Next, we’ll examine how the Q4 earnings update and increased dividend plans could influence Super Group’s...

Recent share performance and business snapshot Crinetics Pharmaceuticals (CRNX) has drawn investor attention after a weak month for the share price, with the stock showing negative returns over the past month and past 3 months despite a positive 1 year total return. The clinical stage company focuses on rare endocrine diseases, with its lead candidate Paltusotine in Phase 3 trials and several earlier stage programs. This context may influence how investors weigh recent share price moves...

In recent days, Coca-Cola Consolidated, the largest Coca-Cola bottler in the US, reached new all-time stock highs following 16 consecutive years of positive revenue growth. This performance highlights how a steady, low-beta bottling business serving 60 million consumers across 14 states can attract considerable investor attention. We’ll now examine how Coca-Cola Consolidated’s 16-year revenue growth streak shapes its investment narrative for current and prospective shareholders. Capitalize...

Immunic (IMUX) is back on investors’ radar after proposing a reverse stock split ahead of an April 14 special shareholder meeting, while management prepares to speak at the Leerink Global Healthcare Conference on March 11. See our latest analysis for Immunic. Those recent corporate updates have come alongside sharp share price moves, with a 1 day share price return of 12.4% and a 30 day share price return of 103.08% contributing to a year to date share price return of 148.71%. However, the 5...

If you are wondering whether Textron's current share price lines up with its underlying worth, this article will walk you through what the numbers are saying and where valuation questions remain. Textron closed at US$93.27, with returns of a 6.1% decline over 7 days, a 2.3% decline over 30 days, 7.1% year to date, 28.4% over 1 year, 41.4% over 3 years, and 69.1% over 5 years. Together, these figures provide context for judging today's price tag. Recent news coverage has focused on Textron's...

In early March 2026, PACS Group, Inc. appointed Patrick H. Conway, MD, MSc, the CEO of Optum and former senior CMS leader, to its Board of Directors, adding a rare mix of clinical, regulatory, and large-scale health system leadership to its governance. This move brings to PACS Group a director who helped design major U.S. value-based payment models and still practices medicine, potentially sharpening the company’s focus on quality and reimbursement innovation in post-acute and skilled...

If you are looking at Advanced Energy Industries and wondering whether the current share price really stacks up, you are not alone. This article will walk through what that price might imply about value. The stock recently closed at US$314.84, with returns of 12.8% over 30 days, 41.8% year to date and 198.4% over the past year, which can change how investors think about both upside and risk. These moves sit against a backdrop of ongoing interest in power conversion and control solutions, as...

In early March 2026, Ouster, Inc. reported its fourth-quarter and full-year 2025 results, delivering US$62.18 million in quarterly revenue and US$3.99 million in net income, and issued first-quarter 2026 revenue guidance of US$45 million to US$48 million while filing an US$84.43 million shelf registration for common stock tied to an ESOP offering. Alongside its first profitable quarter and the acquisition of Stereolabs to broaden its sensor technology beyond lidar, Ouster also saw insider...

If you are wondering whether Magnite's current share price lines up with its underlying value, you are not alone. This article focuses on what the numbers actually say about the stock. The share price closed at US$13.03, with returns of 11.7% over 30 days, a 5.8% decline over 7 days, a nearly flat 0.1% decline over 1 year, a 55.1% gain over 3 years, and a 73.4% decline over 5 years. Recent coverage around Magnite has centered on its role in the ad tech space and how investors are thinking...

Vanda Pharmaceuticals recently received a decision from the U.S. FDA granting a rare formal evidentiary public hearing to review the agency’s proposed refusal to approve a supplemental new drug application for HETLIOZ (tasimelteon) as a treatment for jet lag disorder. This hearing, which follows Vanda’s earlier legal win requiring the FDA to more fully address its clinical evidence, highlights unusually high regulatory and scientific scrutiny around expanding HETLIOZ into a large, currently...

If you are wondering whether Papa John's International is priced attractively right now, it helps to step back and look at what the recent share performance and fundamentals are really telling you. The stock closed at US$38.86 recently, with a sharp 26.1% return over the last 7 days and 11.5% over the last 30 days, while year to date the return sits at a 3.6% decline and the 1 year return is a 7.5% decline, compared to a 46.0% decline over 3 years and a 49.9% decline over 5 years. Recent...

If you are wondering whether Corning's current share price still reflects good value after a strong run, you are not alone. This article is built to help you frame that question clearly. Corning's stock closed at US$131.76, with a 7 day return of a 9% decline, a 30 day return of 0.3%, a year to date return of 45.3% and a 1 year return of 194.6%, while the 3 year and 5 year returns sit at 333.7% and 264.4% respectively. Recent price moves are happening alongside ongoing investor interest in...

If you are wondering whether Amgen's current share price lines up with its underlying worth, this article walks through the key numbers that matter for value focused investors. Amgen's stock last closed at US$377.64, with returns of 15.3% year to date and 24.6% over the past year, while the 7 day and 30 day moves of a 0.4% decline and 0.5% gain suggest recent trading has been relatively steady. Recent headlines around Amgen have focused on its position within large cap pharmaceuticals and...

W. R. Berkley (NYSE:WRB) has appointed Ryan Miller as president of its Berkley Southeast Insurance Group unit. Miller brings over 25 years of commercial insurance operations experience to the regional business. The leadership change is expected to influence management priorities and growth plans in the southeastern U.S. market. For investors tracking W. R. Berkley, the appointment comes at a time when the stock trades at $67.86, with a 1 year return of 13.2% and a 3 year return of 81.4%...

New 52-week high puts recent gains in focus Coda Octopus Group (CODA) has hit a new 52-week high, coinciding with higher operating profit and a firm market position, drawing more investor attention to how the stock’s recent strength lines up with its fundamentals. See our latest analysis for Coda Octopus Group. The share price has slipped back 12.8% over the last day to US$14.62, but that comes after a strong run, with a 90-day share price return of 62.4% and a 1-year total shareholder return...

If you are wondering whether H World Group is still good value at around US$52.05 per share, you are not alone, as many investors are asking the same question after its recent run. The stock has seen a 1% decline over the past week and a 1.4% decline over the last 30 days, yet it is still up 8.5% year to date and 49.5% over the past year. This naturally raises questions about how much of that performance is already reflected in the price. Recent coverage has focused on H World Group's...

In recent days, analysts at UBS and BofA reaffirmed cautious ratings on NNN REIT while highlighting record 2025 acquisitions, stronger-than-expected fourth-quarter results, and the REIT’s 36th consecutive annual dividend increase, even as the share price traded near its 52-week high. At the same time, fresh insider selling by senior leadership and a planned board chair transition are being interpreted as continuity of NNN REIT’s long-term, acquisition-led approach rather than a shift in...